Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

PubWeight™: 1.55‹?› | Rank: Top 4%

🔗 View Article (PMC 1422165)

Published in EMBO J on February 09, 2006

Authors

Jeroen R Mesters1, Cyril Barinka, Weixing Li, Takashi Tsukamoto, Pavel Majer, Barbara S Slusher, Jan Konvalinka, Rolf Hilgenfeld

Author Affiliations

1: Institute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Lübeck, Lübeck, Germany.

Articles citing this

Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69

PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42

Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem (2008) 1.39

Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem (2012) 1.34

PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging (2013) 1.33

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med (2012) 1.29

GCPII imaging and cancer. Curr Med Chem (2012) 1.12

Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem (2009) 1.10

Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.09

The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.08

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res (2014) 1.08

Extracellular proteases as targets for drug development. Curr Protein Pept Sci (2009) 1.02

Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol (2008) 1.01

A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett (2010) 1.01

Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00

A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.98

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics (2015) 0.94

Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93

Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem (2012) 0.93

Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92

Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices. Biomed Microdevices (2012) 0.91

Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett (2012) 0.90

Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Futur HIV Ther (2008) 0.89

X-ray structure of ILL2, an auxin-conjugate amidohydrolase from Arabidopsis thaliana. Proteins (2009) 0.88

Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorg Med Chem Lett (2011) 0.88

Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer. J Drug Target (2013) 0.86

Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS One (2012) 0.84

Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. Bioorg Med Chem Lett (2012) 0.81

[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA). J Med Chem (2015) 0.79

Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates. Macromol Biosci (2012) 0.79

Molecular identification of β-citrylglutamate hydrolase as glutamate carboxypeptidase 3. J Biol Chem (2011) 0.78

Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett (2007) 0.78

Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration. PLoS One (2015) 0.78

Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA). PLoS One (2013) 0.76

The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol (2016) 0.76

The Small Molecule Hyperphyllin Enhances Leaf Formation Rate and Mimics Shoot Meristem Integrity Defects Associated with AMP1 Deficiency. Plant Physiol (2016) 0.76

Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities. FEBS J (2015) 0.75

Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy. Sci Rep (2017) 0.75

Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen. Macromol Res (2013) 0.75

Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme. FASEB J (2013) 0.75

DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening. Nucleic Acids Res (2016) 0.75

N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2). Chem Biol Drug Des (2011) 0.75

Structural and biochemical characterization of a novel aminopeptidase from human intestine. J Biol Chem (2015) 0.75

Articles cited by this

The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88

Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43

XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. J Struct Biol (1999) 17.84

MEROPS: the peptidase database. Nucleic Acids Res (2004) 7.27

ARP/wARP's model-building algorithms. I. The main chain. Acta Crystallogr D Biol Crystallogr (2002) 3.84

Automated structure solution, density modification and model building. Acta Crystallogr D Biol Crystallogr (2002) 3.67

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem (2004) 3.49

Dictionary of recurrent domains in protein structures. Proteins (1998) 3.40

Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem (1984) 3.39

Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 2.38

Dileucine-based sorting signals bind to the beta chain of AP-1 at a site distinct and regulated differently from the tyrosine-based motif-binding site. EMBO J (1998) 2.27

Crystal structure of the ectodomain of human transferrin receptor. Science (1999) 2.19

Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature (2000) 2.14

The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther (1999) 2.03

Utility of homology models in the drug discovery process. Drug Discov Today (2004) 1.98

Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88

Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med (1999) 1.79

The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71

Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A (1996) 1.70

Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem (1987) 1.64

The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A (2003) 1.62

A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60

Crystal structure of Aeromonas proteolytica aminopeptidase: a prototypical member of the co-catalytic zinc enzyme family. Structure (1994) 1.58

Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem (1996) 1.52

Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A (2005) 1.49

Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43

N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem (1997) 1.42

A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol (2001) 1.39

Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem (2004) 1.29

Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology (1997) 1.25

Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci (1993) 1.25

Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins. Proc Natl Acad Sci U S A (2001) 1.22

Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res (2003) 1.22

Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem (2001) 1.21

Streptomyces griseus aminopeptidase: X-ray crystallographic structure at 1.75 A resolution. J Mol Biol (1997) 1.18

Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A (2003) 1.18

Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate (1999) 1.17

Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem (2002) 1.17

Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate Suppl (1996) 1.17

The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis (1997) 1.13

Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem (2003) 1.12

Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci (2004) 1.09

Structure of membrane glutamate carboxypeptidase. Biochim Biophys Acta (1997) 1.07

Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke (1990) 1.05

GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci (2002) 1.02

The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J (2001) 1.01

Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol (1997) 1.00

Design of NAALADase inhibitors: a novel neuroprotective strategy. Curr Med Chem (2001) 0.99

Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol (1999) 0.98

Co-catalytic metallopeptidases as pharmaceutical targets. Curr Opin Chem Biol (2003) 0.98

Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res (2001) 0.98

The immunocytochemical localization of N-acetylaspartyl glutamate, its hydrolysing enzyme NAALADase, and the NMDAR-1 receptor at a vertebrate neuromuscular junction. Neuroscience (1995) 0.97

Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem (1990) 0.96

Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience (2001) 0.94

Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate (2003) 0.93

Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther (2002) 0.92

Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. Neuropeptides (2003) 0.91

Low-concentration N-acetylaspartylglutamate suppresses the climbing fiber response of Purkinje cells in guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Res (1989) 0.88

Enantiospecificity of glutamate carboxypeptidase II inhibition. J Med Chem (2005) 0.86

Inhibition of Streptomyces griseus aminopeptidase and effects of calcium ions on catalysis and binding--comparisons with the homologous enzyme Aeromonas proteolytica aminopeptidase. Eur J Biochem (1998) 0.83

Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors. J Med Chem (2002) 0.82

N-acetyl-aspartylglutamate modulation of N-methyl-D-aspartate-stimulated [3H]norepinephrine release from rat hippocampal slices. J Pharmacol Exp Ther (1993) 0.82

Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur J Neurosci (1995) 0.81

Mechanisms for clearance of released N-acetylaspartylglutamate in crayfish nerve fibers: implications for axon-glia signaling. Neuroscience (2001) 0.81

Structural and functional stability of the mature transferrin receptor from human placenta. Arch Biochem Biophys (2001) 0.76

Articles by these authors

Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science (2003) 3.92

The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 3.81

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A (2003) 3.02

Rice plants take up iron as an Fe3+-phytosiderophore and as Fe2+. Plant J (2006) 2.82

Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J (2007) 2.52

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J (2002) 2.30

Accumulation of free ADP-ribose from mitochondria mediates oxidative stress-induced gating of TRPM2 cation channels. J Biol Chem (2004) 2.08

Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol (2012) 2.07

Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med (2007) 1.99

Utility of homology models in the drug discovery process. Drug Discov Today (2004) 1.98

High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging (2005) 1.97

Conformational antagonism between opposing active sites in a bifunctional RelA/SpoT homolog modulates (p)ppGpp metabolism during the stringent response [corrected]. Cell (2004) 1.95

Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res (2009) 1.87

Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol (2009) 1.81

Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol (2005) 1.73

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest (2015) 1.67

Rice metal-nicotianamine transporter, OsYSL2, is required for the long-distance transport of iron and manganese. Plant J (2010) 1.66

Mutational reconstructed ferric chelate reductase confers enhanced tolerance in rice to iron deficiency in calcareous soil. Proc Natl Acad Sci U S A (2007) 1.54

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther (2010) 1.48

Structural basis for the regulation of cysteine-protease activity by a new class of protease inhibitors in Plasmodium. Structure (2011) 1.46

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res (2009) 1.44

Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today (2007) 1.42

Biosynthesis and secretion of mugineic acid family phytosiderophores in zinc-deficient barley. Plant J (2006) 1.41

Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol (2012) 1.39

Synthesis and biological evaluation of D-amino acid oxidase inhibitors. J Med Chem (2008) 1.29

A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc (2010) 1.29

Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Curr Pharm Des (2011) 1.28

Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry (2009) 1.27

Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem (2012) 1.27

Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors. Virology (2005) 1.23

Deoxymugineic acid increases Zn translocation in Zn-deficient rice plants. Plant Mol Biol (2008) 1.22

Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res (2011) 1.21

Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol (2014) 1.21

Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants. J Mol Biol (2007) 1.19

Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A (2003) 1.18

Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem (2002) 1.17

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog (2011) 1.14

Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem (2002) 1.14

Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. J Neurochem (2007) 1.13

Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem (2003) 1.12

Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem (2009) 1.11

Antiviral strategies to control calicivirus infections. Antiviral Res (2010) 1.11

From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc Natl Acad Sci U S A (2005) 1.11

Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem (2009) 1.10

Current and Novel Inhibitors of HIV Protease. Viruses (2009) 1.10

Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci (2004) 1.09

pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J Mol Biol (2005) 1.09

Structural and functional characterization of Falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum. J Biol Chem (2006) 1.09

Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2013) 1.08

Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem (2007) 1.08

Czech bibliometric system fosters mediocre research. Nature (2009) 1.08

Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region. J Virol (2008) 1.08

Dual substrate and reaction specificity in mouse serine racemase: identification of high-affinity dicarboxylate substrate and inhibitors and analysis of the beta-eliminase activity. Biochemistry (2005) 1.07

Exoerythrocytic Plasmodium parasites secrete a cysteine protease inhibitor involved in sporozoite invasion and capable of blocking cell death of host hepatocytes. PLoS Pathog (2010) 1.07

Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. J Neurosci (2011) 1.06

GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J Neurophysiol (2003) 1.05

Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther (2013) 1.05

Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem Biophys Res Commun (2004) 1.03

3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol (2013) 1.03

Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice. Drug Metab Dispos (2012) 1.02

The active principle of garlic at atomic resolution. J Biol Chem (2002) 1.02

Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol (2008) 1.01

Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res (2009) 1.01

Phosphonate and phosphinate analogues of N-acylated gamma-glutamylglutamate. potent inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett (2002) 1.01

Inhibition of human serine racemase, an emerging target for medicinal chemistry. Curr Drug Targets (2011) 1.00

Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00

Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J Virol (2009) 0.99

Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem (2007) 0.98

A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.98

Biochemical and functional analyses of the Mip protein: influence of the N-terminal half and of peptidylprolyl isomerase activity on the virulence of Legionella pneumophila. Infect Immun (2003) 0.97

Architecture and regulation of HtrA-family proteins involved in protein quality control and stress response. Cell Mol Life Sci (2012) 0.97

Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. J Mol Biol (2002) 0.96

A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. Chem Biol (2008) 0.96